Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

St. Anthony Hospital installs Toshiba America Medical Systems' Vantage Titan MR system

To provide the latest in MR technology to its patient community, St. Anthony Hospital in Gig Harbor, Wash. installed the Vantage TitanTM from Toshiba America Medical Systems, Inc. to offer comprehensive MR patient exams. The new 80-bed St. Anthony hospital is the only full service facility in the area and needed a workhorse MR system to conduct a full range of exams.

18 Oct 2009

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Inspire Pharmaceuticals, Inc. announced today Inspire scientists and collaborators will present data from the denufosol tetrasodium cystic fibrosis (CF) program in a poster presentation at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) October 15 - 17, 2009 in Minneapolis, MN.

15 Oct 2009

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.

15 Oct 2009

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

D. Porpoise Evans, a litigation associate in the Miami office of the international law firm Greenberg Traurig P.A., has been named among the "40 Under 40" outstanding lawyers of Miami-Dade County by the Cystic Fibrosis Foundation (CFF). The 40 lawyers will be honored at the CFF benefit dinner on November 20, 2009 at the Intercontinental Hotel in Miami.

14 Oct 2009

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

The University of North Carolina at Chapel Hill has been awarded a five-year, $6.2 million renewal grant to continue its work as part of the National Institutes of Health's Rare Diseases Clinical Research Network (RDCRN).

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

University of Nottingham pioneers new type of MRI scan

People with chronic lung disease and asthma could soon be offered better treatment thanks to a new type of Magnetic Resonance Imaging (MRI) scan being pioneered at The University of Nottingham.

13 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

New technique may lead to more effective treatment for liver disease

A combination of bioengineering and medical research at the University of California, San Diego has led to a new discovery that could pave the way for more effective treatments for liver disease.

12 Oct 2009

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

The Riley Hospital for Children Cystic Fibrosis Center is the first site in the nation to enroll patients ages 6-11 for the first part of a 48-week clinical trial of a promising investigational treatment for cystic fibrosis (CF).

9 Oct 2009

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

9 Oct 2009

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Lpath, Inc., the category leader in lipidomics-based therapeutics, reported positive summary results of its single-dose Phase 1 clinical trial of iSONEP™ in wet-AMD patients.

8 Oct 2009

Aeolus Pharmaceuticals’ AEOL 10150 effective against mustard gas exposure

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and Lovelace Respiratory Research Institute have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from whole mustard gas exposure in rats. Data were presented at the Regional CounterACT Countermeasures Against Chemical Threats Conference in Albuquerque, NM.

8 Oct 2009

Multi-center Lung Genomics Research Consortium to study fatal lung diseases

Researchers at five research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

NHLBI awards $11 million to research on the biology of two fatal lung diseases

Researchers at National Jewish Health and four other research centers have been awarded an $11 million, two-year grant from the National Heart Lung and Blood Institute as part of the NIH Recovery Act that will allow a team of national scientists to delve deeply into the biology of two fatal lung diseases for which there are few therapeutic options.

8 Oct 2009

HDSA honors outstanding contributors against Huntington's Disease

The Huntington's Disease Society of America (HDSA), will recognize the outstanding contributions to improving the quality of life of people with Huntington's Disease (HD) by several individuals and two organizations at the 13th annual Guthrie Awards Dinner this Thursday.

7 Oct 2009

Research to explore diagnosis and treatment of rare diseases

The National Institutes of Health announced today a second phase of the Rare Diseases Clinical Research Network (RDCRN) including funds for 19 research consortia.

7 Oct 2009

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) (the “Company”), today announced that it has closed a $325,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date to approximately $3.8 million.

7 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Fibrosis News and Research

Further Reading

St. Anthony Hospital installs Toshiba America Medical Systems' Vantage Titan MR system

Inspire to present its denufosol tetrasodium cystic fibrosis program data at the 23rd NACFC

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Cystic Fibrosis Foundation honors Greenberg Traurig attorney D. Porpoise Evans

University of North Carolina awarded grant to continue research on rare disease-causing gene mutations

Older generation antibiotic for treating colon cancer

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

University of Nottingham pioneers new type of MRI scan

Wake Forest University School of Medicine honours researchers

New technique may lead to more effective treatment for liver disease

Riley Hospital for Children commences patient enrollment in clinical trial of cystic fibrosis drug

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Lpath reports positive Phase 1 clinical trial results of iSONEP in wet-AMD patients

Aeolus Pharmaceuticals’ AEOL 10150 effective against mustard gas exposure

Multi-center Lung Genomics Research Consortium to study fatal lung diseases

NHLBI awards $11 million to research on the biology of two fatal lung diseases

HDSA honors outstanding contributors against Huntington's Disease

Research to explore diagnosis and treatment of rare diseases

Pro-Pharmaceuticals closes $325,000 tranche of private placement; total raised to $3.8 million

Schering-Plough receives FDA recommendation approval for PEGINTRON

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News